Absci (ABSI) now expects a gross use of cash, cash equivalents, and short-term investments of approximately $75 million, below the previous ...

TD Cowen analyst Brendan Smith maintained a Buy rating on AbSci (ABSI – Research Report) today. The company’s shares opened today at $4.10. Smith covers the Healthcare sector, focusing on stocks such ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

Expected Gross Use of Cash for 2024: Approximately $75 million, revised down from $80 million. Absci Corp (NASDAQ:ABSI) achieved a significant milestone in its collaboration with AstraZeneca by ...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody ...

Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago. These figures ...

DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.

Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its ...

Good day, and thank you for standing by. Welcome to the Absci Q3 2024 business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now ...

and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended ...